Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 3069 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 3371 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 4017 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 4379 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 5621 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 5707 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 5725 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 5786 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 6361 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 6644 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 6997 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 7023 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 7094 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 7131 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 7801 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 7840 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 8293 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 8803 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 8817 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 9057 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 9984 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 10549 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 11866 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 12529 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 13375 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | BILIVERDIN (M-H)- | 18150 | Peak area normalized | male | Diabetic | no neuropathy |